August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology

Access and adherence to long-term cancer therapies are emerging as major public health issues around the world, as high out-of-pocket costs for oral oncolytics are linked to nonadherence that can directly affect patient outcomes, said Dawn L. Hershman, MD, MS, Professor of Medicine and Epidemiology, Columbia University Medical Center, New York, NY, at ASCO 2016.
Read Article

In her presidential address, Julie M. Vose, MD, MBA, Chief of the Oncology/Hematology Division, University of Nebraska Medical Center, Omaha, highlighted the importance of multimodal care and its effect on the quality of care and enhancement of clinical trial participation among patients with cancer.
Read Article

Page 3 of 3